Our Mission

The mission of PPMI is to identify one or more biomarkers of Parkinson’s disease progression. The discovery of a biomarker is a critical step in the development of new and better treatments for PD. This study is being sponsored by The Michael J. Fox Foundation for Parkinson's Research.

PPMI Enrollment Status

Prodromal Participants
Enrollment Goal: 100

Genetic Cohort Participants
Enrollmen Goal: 600

Genetic Registry Participants
Enrollment Goal: ~600

De Novo PD Participants
Enrollment Goal: 400

Control Participants
Enrollment Goal: 200

Subjects with SWEDD
Enrollment: 64

Last Update: July 22, 2014


More about study cohorts >


Welcome to the Parkinson’s Progression Markers Initiative (PPMI), a landmark observational clinical study to comprehensively evaluate cohorts of significant interest using advanced imaging, biologic sampling and clinical and behavioral assessments to identify biomarkers of Parkinson’s disease progression.

PPMI is taking place at clinical sites in the United States, Europe, Israel, and Australia. Data and samples acquired from study participants will enable the development of a comprehensive Parkinson’s database and biorepository, which is currently available to the scientific community to conduct field-changing research.

PPMI is made possible by the concerted efforts of a number of collaborators. This study is sponsored by The Michael J. Fox Foundation for Parkinson’s Research.

Learn more about Who We Are.


Funding and Biospecimens Access Opportunity

The Michael J. Fox Foundation for Parkinson’s Research has supported several pre-clinical and clinical efforts that have generated valuable data, biospecimens, and tissue resources for the research community. Qualified researchers may request access to these resources (including PPMI) with or without funding requests by using a single application through Access Data & Biospecimens. Deadline: August 11. Informational call: July 28.

MDS 2014 PPMI Presentations are Live

The PPMI presentations and posters from the International Parkinson and Movement Disorders Society’s 18th annual congress are now available in Presentations.

PPMI Annual Meeting 2014 Summary

On May 6 and 7, PPMI held its 2014 Annual Investigators Meeting in New York, NY. Participants included site investigators and coordinators, study and sponsor staff, industry partners, and Steering Committee, Patient Advisory Committee, and study core members representing 15 countries and about 60 companies and organizations. View this year’s presentations.

PPMI Presentations at MDS 2014 Stockholm

PPMI will be well-represented at the International Parkinson and Movement Disorders Society’s upcoming 18th annual congress happening June 8-12 in Stockholm, Sweden. Find out when and where to view the PPMI posters and presentations.

Participant Newsletter & CSF Teleconference Posted

The latest PPMI participant newsletter and study update call have been posted to the Enrolled Participants page. These detail the genetics cohort, research using PPMI cerebrospinal fluid (CSF), and more.

Learn More